TY - JOUR
T1 - Plasma levels of alpha-1-antichymotrypsin are elevated in patients with chronic heart failure, but are of limited prognostic value
AU - Lok, S.I.
AU - Lok, D.J.
AU - van der Weide, P.
AU - Winkens, B.
AU - Bruggink-André de la Porte, P.W.
AU - Doevendans, P.A.
AU - de Weger, R.A.
AU - van der Meer, P.
AU - de Jonge, N.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background There is increasing interest in utilising novel markers of cardiovascular disease risk in patients with chronic heart failure (HF). Recently, it was shown that alpha-1-antichymotrypsin (ACT), an acute-phase protein and major inhibitor of cathpesin G, plays a role in the pathophysiology of HF and may serve as a marker for myocardial distress. Objective To assess whether ACT is independently associated with long-term mortality in chronic HF patients. Methods ACT plasma levels were categorised into quartiles. Survival times were analysed using Kaplan-Meier curves and Cox proportional hazards regression, without and with correction for clinically relevant risk factors, including sex, age, duration of HF, kidney function (MDRD), ischaemic HF aetiology and NT-proBNP. Results Twenty healthy individuals and 224 patients (mean age 71 years, 72 % male, median HF duration 1.6 years) with chronic HF were included. In total, 159 (71 %) patients died. The median survival time was 5.3 (95 % CI 4.5-6.1) years. ACT was significantly elevated in patients (median 433 mu g/ml, IQR 279-680) in comparison with controls (median 214 mu g/ml, IQR 166-271; p
AB - Background There is increasing interest in utilising novel markers of cardiovascular disease risk in patients with chronic heart failure (HF). Recently, it was shown that alpha-1-antichymotrypsin (ACT), an acute-phase protein and major inhibitor of cathpesin G, plays a role in the pathophysiology of HF and may serve as a marker for myocardial distress. Objective To assess whether ACT is independently associated with long-term mortality in chronic HF patients. Methods ACT plasma levels were categorised into quartiles. Survival times were analysed using Kaplan-Meier curves and Cox proportional hazards regression, without and with correction for clinically relevant risk factors, including sex, age, duration of HF, kidney function (MDRD), ischaemic HF aetiology and NT-proBNP. Results Twenty healthy individuals and 224 patients (mean age 71 years, 72 % male, median HF duration 1.6 years) with chronic HF were included. In total, 159 (71 %) patients died. The median survival time was 5.3 (95 % CI 4.5-6.1) years. ACT was significantly elevated in patients (median 433 mu g/ml, IQR 279-680) in comparison with controls (median 214 mu g/ml, IQR 166-271; p
U2 - 10.1007/s12471-014-0584-2
DO - 10.1007/s12471-014-0584-2
M3 - Article
C2 - 25172361
SN - 1568-5888
VL - 22
SP - 391
EP - 395
JO - Netherlands Heart Journal
JF - Netherlands Heart Journal
IS - 9
ER -